Last reviewed · How we verify
NCT05600049
Tolerance and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots
NA trial testing Prototypes (815-v1 001) to (815-v1 050) in Lentigo Solar in 33 participants. Completed in 8 June 2023.
8 June 2023
Quick facts
| Lead sponsor | Cryonove Pharma |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 33 |
| Start date | 21 October 2022 |
| Primary completion | 8 June 2023 |
| Estimated completion | 8 June 2023 |
| Sites | 1 location across Georgia |
Drugs / interventions tested
- Prototypes (815-v1 001) to (815-v1 050)
- Prototype (815-v1 051) to (815-v1 100)
- Prototypes (815-v1 101) to (815-v1 150)
- Prototypes (815-v1 151) to (815-v1 200)
Conditions studied
- Lentigo Solar — all drugs for Lentigo Solar →
Sponsor
Cryonove Pharma
Who can join
Adults 30 to 75, any sex, with Lentigo Solar. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
CS5\_1 study aim to evaluate the tolerance and to adjust the mode of administration of 4 different conditions of cryotherapy treatments applied on the brown spots of the face and hand with 3 prototypes. Each treatment corresponds to a combination of a specific sequence of a cryogenic spray and of a frequency of application. The study will evaluate 3 prototypes : * Prototype 1 : from (815-v1 001) to (815-v1 100) * Prototype 2 : from (815-v1 101) to (815-v1 150) * Prototype 3 : from (815-v1 151) to (815-v1 200)
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05600049
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Cryonove Pharma trials
Trials by the same sponsor.
- NCT06361251 — Interventional, Monocentric, Double-blind Randomized Category 2b Study Evaluating the Evaluation of the Tolerance of Cyt · NA · completed
- NCT05886010 — Performance and Tolerance of Cyto-selective Difluoroethane-based Cryotherapy in th Treatment of Brown Spots (Solar and S · NA · unknown
- NCT05883657 — Tolerance and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots (Solar and · NA · unknown
- NCT05625815 — Tolerance and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots. · NA · completed
- NCT05793619 — Tolerance and Performance (Mode of Administration) of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment o · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05600049 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cryonove Pharma
- Last refreshed: 15 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05600049.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing